Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

Hepatology (Baltimore, Md.) - 1 Jun 2005

Brunelle Marie-Noëlle, Jacquard Anne-Carole, Pichoud Christian, Durantel David, Carrouée-Durantel Sandra, Villeneuve Jean-Pierre, Trépo Christian, Zoulim Fabien

Abstract excerpt

Mutations within the hepatitis B virus (HBV) polymerase gene conferring drug-resistance are selected during prolonged lamivudine (3TC) or adefovir dipivoxil (ADV) treatment. Because there is no other approved drug against HBV, treatments with 3TC or ADV are used either sequentially or in addition, depending on treatment response or failure. Considering the use of de novo or add-on 3TC+ADV bitherapy, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B virus

Share to Lamivudine

Share to Nucleosides

Share to Nucleotides

Share to Organophosphonates

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 15915463
DOI: 10.1002/hep.20723

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.PMID 15915463Read ↗

In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.Semantic proximity Read ↗

Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.Semantic proximity Read ↗

In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.Semantic proximity Read ↗

Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants.Semantic proximity Read ↗

Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.Semantic proximity Read ↗

Treatment for hepatitis B in patients with drug resistanceSemantic proximity Read ↗

Pathobiology of HBV mutants and clinical impact for treatment monitoring.Semantic proximity Read ↗

Antiviral drug resistance: clinical consequences and molecular aspects.Semantic proximity Read ↗

Increased occurrence of mutant rtI233V of HBV in patients receiving adefovir therapy.Semantic proximity Read ↗

Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.Semantic proximity Read ↗

Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistanceSemantic proximity Read ↗

Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.